ATE453407T1 - Anti-ccr7-rezeptor-antikörper zur krebsbehandlung - Google Patents

Anti-ccr7-rezeptor-antikörper zur krebsbehandlung

Info

Publication number
ATE453407T1
ATE453407T1 AT06776128T AT06776128T ATE453407T1 AT E453407 T1 ATE453407 T1 AT E453407T1 AT 06776128 T AT06776128 T AT 06776128T AT 06776128 T AT06776128 T AT 06776128T AT E453407 T1 ATE453407 T1 AT E453407T1
Authority
AT
Austria
Prior art keywords
ccr7 receptor
cancer treatment
receptor antibodies
antibodies
ccr7
Prior art date
Application number
AT06776128T
Other languages
German (de)
English (en)
Inventor
Calleja Cecilia Munoz
Perez Manuel Jesus Alfonso
Giral Sonia Lapez
Original Assignee
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Autonoma filed Critical Univ Madrid Autonoma
Application granted granted Critical
Publication of ATE453407T1 publication Critical patent/ATE453407T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06776128T 2005-07-06 2006-07-05 Anti-ccr7-rezeptor-antikörper zur krebsbehandlung ATE453407T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
PCT/EP2006/006556 WO2007003426A1 (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE453407T1 true ATE453407T1 (de) 2010-01-15

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06776128T ATE453407T1 (de) 2005-07-06 2006-07-05 Anti-ccr7-rezeptor-antikörper zur krebsbehandlung

Country Status (16)

Country Link
US (1) US8066996B2 (https=)
EP (1) EP1904102B1 (https=)
JP (1) JP5249025B2 (https=)
KR (1) KR20080030655A (https=)
CN (1) CN101257923A (https=)
AT (1) ATE453407T1 (https=)
AU (1) AU2006265281C1 (https=)
BR (1) BRPI0612632A2 (https=)
CA (1) CA2614080C (https=)
DE (1) DE602006011466D1 (https=)
DK (1) DK1904102T3 (https=)
ES (1) ES2338919T3 (https=)
IL (1) IL188594A (https=)
PT (1) PT1904102E (https=)
RU (1) RU2404808C2 (https=)
WO (2) WO2007003216A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
EP2285403A2 (en) * 2008-05-14 2011-02-23 Msm Protein Technologies, Inc. Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
WO2011040428A1 (ja) * 2009-09-29 2011-04-07 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
AU2011309114B2 (en) * 2010-09-28 2015-03-19 Nb Health Laboratory Co., Ltd. Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP2970483A2 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
JP6618191B2 (ja) * 2014-03-27 2019-12-11 国立研究開発法人医薬基盤・健康・栄養研究所 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
BR112018002877A2 (en) 2015-08-10 2018-11-06 Pepmab B.V. humanized ccr7 receptor antibodies
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US20220064311A1 (en) * 2018-12-18 2022-03-03 Catapult Therapeutics B.V. The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD)
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
US7807784B2 (en) * 2003-06-11 2010-10-05 The University Of Chicago Increased T-cell tumor infiltration by mutant LIGHT

Also Published As

Publication number Publication date
DE602006011466D1 (de) 2010-02-11
RU2008104420A (ru) 2009-08-20
AU2006265281C1 (en) 2012-11-15
AU2006265281B2 (en) 2012-03-01
BRPI0612632A2 (pt) 2012-01-03
US20090123483A1 (en) 2009-05-14
ES2338919T3 (es) 2010-05-13
CN101257923A (zh) 2008-09-03
JP2008545000A (ja) 2008-12-11
JP5249025B2 (ja) 2013-07-31
EP1904102B1 (en) 2009-12-30
IL188594A (en) 2012-02-29
CA2614080A1 (en) 2007-01-11
WO2007003426A1 (en) 2007-01-11
AU2006265281A1 (en) 2007-01-11
US8066996B2 (en) 2011-11-29
DK1904102T3 (da) 2010-04-19
IL188594A0 (en) 2008-04-13
CA2614080C (en) 2014-08-26
KR20080030655A (ko) 2008-04-04
WO2007003216A1 (en) 2007-01-11
EP1904102A1 (en) 2008-04-02
PT1904102E (pt) 2010-03-29
RU2404808C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
IL188594A0 (en) Anti-ccr7 receptor antibodies for the treatment of cancer
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MX373790B (es) Anticuerpos humanos a ligando de muerte programada 1 (pd-l1).
BR112016025437A2 (pt) combinação de lenalidomida e construto de polipeptídeo, e usos destes
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
MD4748B1 (ro) Terapii imunooncolitice
MX385545B (es) Anticuerpos humanos para pd-1.
BRPI0919473A2 (pt) Agentes de ligação frizzled e usos dos mesmos
EA200971077A1 (ru) Гетероциклические модуляторы киназы
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201591762A1 (ru) Человеческие антитела к grem1
EA200600869A1 (ru) Антитела, связывающие рецептор интерлейкина-4
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
UY31466A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
EA201171237A1 (ru) Антитела к dkk-1
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1904102

Country of ref document: EP